Affordable Access

deepdyve-link
Publisher Website

Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital.

Authors
  • Gosiengfiao, Yasmin
  • Reichek, Jennifer
  • Woodman, Jill
  • Ben-Ami, Tamar
  • Walterhouse, David
Type
Published Article
Journal
Journal of Pediatric Hematology/Oncology
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Mar 01, 2012
Volume
34
Issue
2
Identifiers
DOI: 10.1097/MPH.0b013e3182331ee8
PMID: 22217487
Source
Medline
License
Unknown

Abstract

It remains unclear how to optimally incorporate gemcitabine and docetaxel into the management of patients with recurrent osteosarcoma. We describe 4 pediatric patients with recurrent osteosarcoma who were treated with gemcitabine ± docetaxel and resection. One patient had a partial response and 2 had stable disease. Two patients subsequently underwent surgical resections. Median duration of response was 8 months and was longer for patients who underwent resection. One patient remains disease-free 57 months from recurrence. Our limited series provides additional support for the use of gemcitabine ± docetaxel for recurrent osteosarcoma and suggests benefit of concurrent local control measures if possible.

Report this publication

Statistics

Seen <100 times